Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasatinib + blinatumomab
- Development stage
- Unknown
- Lead developer
- GIMEMA
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Dasatinib + blinatumomab is a chemotherapy-free combination regimen investigated by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The regimen consists of dasatinib, a second-generation tyrosine kinase inhibitor that targets the BCR-ABL1 protein, and blinatumomab, a bispecific T-cell engager (BiTE) that targets CD19 on B cells and CD3 on T cells. In the GIMEMA LAL2116 (D-ALBA) trial, dasatinib is administered as induction therapy followed by blinatumomab consolidation. This approach aims to achieve high rates of molecular response and long-term survival while avoiding the toxicities associated with intensive chemotherapy.
- Brand names
- SprycelBlincyto
- Other names
- D-ALBA regimendasatinib plus blinatumomabdasatinib + blinatumomab-Gruppo Italiano Malattie EMatologiche dell'Adulto-acute lymphoblastic leukemia
02
Targets
CD19 (B lymphocyte antigen CD19)LCK (Proto-oncogene tyrosine-protein kinase Lck)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on dasatinib + blinatumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasatinib + blinatumomab.